- BioMarin will receive an exclusive license to each program for research, development, and commercialization of the gene therapies
- The collaboration will utilize Allen institute technologies to develop new gene therapies for rare genetic diseases of CNS by targeting gene expression to specific cells
- Allen Institute has developed modified engineering AAVs to carry genes on specific types of neurons or other cells in the brain
Click here to read full press release/ article | Ref: BioMarin | Image: BioMarin
The post BioMarin Collaborates with Allen Institute to Develop Gene Therapies for Rare Brain Diseases first appeared on PharmaShots.